Hypertension Studies

  1. Evaluation of efficacy and safety of 5 mg and 10 mg dose levels of XXX vs placebo in patients with hypertension.
  2. A single-blind ascending dose-response and safety tolerance study of oral XX44-655 in patients with mild-to-moderate essential hypertension.
  3. Double-blind placebo and positive-controlled study in patients with mild-to-moderate hypertension comparing once-daily dosing of XX-16617 (5 mg and 20 mg) with hydrochlorothiazide 50 mg and placebo.
  4. Evaluation of efficacy and safety of XXX in combination with hydrochlorothiazide in patients with essential hypertension.
  5. Evaluation of efficacy and safety of XXX phase doseTM in mild-to-moderate hypertension.
  6. Comparison of XXX vs HCTZ in elderly hypertensives using 24-hr ABPM.
  7. Once daily XXX in the treatment of mild-to-moderate hypertension: A double-blind placebo-controlled parallel group dose-ranging study.
  8. Evaluation of various once daily dosages of XX-10085 an ACE inhibitor, in patients with essential hypertension.
  9. Multicenter evaluation of the safety and once-daily (100 mg and 200 mg) efficacy of XXX modified release (XXX) capsule, compared with placebo in the treatment of essential hypertension.
  10. Pilot 3 week oral dose-ranging study of XX93522-004 once a day, in mildly to moderately hypertensive patients.
  11. A multinational placebo controlled double-blind dose response study to determine the anti-hypertensive effects of XXX 25,50,75 or 100 mg given once daily in addition to atenolol 100 mg in patients inadequately controlled on atenolol 100 mg.
  12. XXX vs. verapamil sustained-release in elderly patients with mild hypertension.
  13. A multicenter, double-blind randomized, placebo-controlled parallel clinical study to determine the dose-response relation-ship of XXX in patients with mild to moderate hypertension.
  14. A one-week double-blind evaluation of the safety and pharmacologic activity of multiple oral doses of XX 21891 in hypertensive and hypercholesterolemic patients.
  15. Multicenter, placebo controlled study evaluating the dose response of XXXat higher doses.
  16. A placebo-controlled, double-blind, parallel-group pilot study to determine the safety and blood pressure lowering effects and pharmacokinetics of XXX 200 mg q.d. or 100 mg b.i.d. in hypertensive patients who are uncontrolled on atenolol 100 mg q.d.
  17. Multicenter evaluation of the safety and once-daily dose ranging of XXX modified release GITS tablet, compared with placebo, in the treatment of essential hypertension.
  18. The pharmacodynamics, steady state pharmacokinetics and tolerance of XXX GITS controlled release formulation.        
  19. The safety and efficacy of XXX tablets administered BID vs placebo in essential hypertension.
  20. XXX in the treatment of essential hypertension.
  21. A randomized, double-blind study of the safety and antihypertensive efficacy of concomitant XXX and XXX extended release (ER) compared to XXX in patients with mild to moderate essential hypertension.
  22. XXX as an adjunct to Enalapril therapy in patients with mild-to-moderate hypertension.
  23. An open-label assessment of the safety and efficacy of XXX in the treatment of patients with mild to moderate hypertension.
  24. A multicenter double-blind placebo controlled, two panel, parallel group, inpatient study to investigate the safety and antihypertensive efficacy of multiple doses of AII antagonist XXXin patients with mild to moderate essential hypertension.
  25. A double-blind, randomized parallel, placebo-controlled study to investigate the antihypertensive efficacy and safety of different doses of XXX.
  26. A double-blind, placebo-controlled, parallel group anti-hypertensive safety and efficacy study of XXX 1.25 mg.
  27. A double-blind, placebo controlled, parallel group antihypertensive safety and efficacy study of XXX 1.25 mg in patients over 50 years of age.
  28. A randomized, double-blind placebo controlled, parallel group comparison of monotherapy and combined therapy of XXX 5 mg once daily and XXX 2.5 mg once daily for treatment of patients with essential hypertension.
  29. Comparative effects of XXX CD and XXX SR as once a day antihypertensive therapy.
  30. A double-blind, placebo-controlled, parallel group dose ranging safety and efficacy study of a once daily dose of XXXin patients with mild to moderate essential hypertension.
  31. Evaluation of therapy conversion from XXX IR (immediate release) to XXX HC1 SR (sustained release) in hypertensive patients.
  32. A multicenter, double-blind randomized, placebo-controlledclinical study to evaluate the antihypertensive efficacy and safety of XXX in patients with mild to moderate hypertension (acute and long term).
  33. Efficacy and safety evaluation of four doses of GITS XXX in the treatment of mild hypertension.
  34. A randomized, placebo-controlled double-blind parallel study comparing the antihypertensive efficacy and safety of XXX extended release (ER) (XXX hour formulation monotherapy), XXX monotherapy and the combination of XXX ER and XXX in patients with mild to moderate hypertension.
  35. Multicenter trial to determine the efficacy, tolerance and safety of three different doses of XXX, a new presynaptic DA2-Agonist, compared with placebo in outpatients with mild to moderate essential hypertension.
  36. Double-blind, randomized trial comparing XXX vs XXX in mild to moderate essential hypertensive patients with a history of ACE inhibitor-associated cough.
  37. A double-blind, placebo-controlled, parallel study to evaluate the pharmacodynamic activity of intravenous XXX an angiotensin II receptor antagonist, in hypertensive patients.
  38. A randomized, double-blind, placebo controlled, multicenter study of the safety and antihypertensive efficacy of concomitant treatment with XXX ER and XXX in patients with mild to moderate essential hypertension.
  39. A study for evaluation of therapy conversion from XXX 2.5 mg to XXX 1.25 mg in mild to moderate hypertensive patients.
  40. A multicenter study of the safety and antihypertensive efficacy of XXX 5 mg combined with XXX ER 120 or 180 mg in patients with severe hypertension (acute and long term).
  41. A comparison of XXX vs XXX CD and Placebo for the treatment of essential hypertension.
  42. Comparison of XXX sodium and XXX GITS in older patients with mild to moderate essential hypertension with the addition of low dose hydrochlorothiazide for non responders.
  43. Hemodynamic effects of XXX, a combined alpha and beta adrenergic recepto antagonist, in young and elderly hypertensives during exercise and rest.
  44. A randomized, forced titration, placebo-controlled study of XXX HCl (XXX) in patients with mild to moderate hypertension with doses up to 720 mg administered as once daily and twice daily regimens.
  45. A randomized, double-blind parallel, multicenter study to compare safety and efficacy of XXX and hydrochlorothiazide in postmenopausal women.
  46. A randomized, double-blind, placebo-controlled, factorial design dose-response study of XXX HCl (CS-622) alone or in combination with hydrochlorothiazide in patients with mild to moderate essential hypertension.
  47. XXX/enalapril combination therapy in hypertensive patients not responding adequately to XXX monotherapy.
  48. A randomized, double-blind, placebo-controlled, parallel study of the safety and antihypertensive efficacy of multiple doses of XXX, an angiotensin II receptor blocker, compared to XXX and placebo in patients with mild to moderate hypertension.
  49. A randomized, double-blind, placebo-controlled, parallel, multicenter study of XXX in postmenopausal hypertensive women who are using hormone replacement therapy.
  50. A Phase II, double-blind, placebo-controlled, dose-range and short-term efficacy study of XXX in hypertensive patients.
  51. A double-blind ambulatory blood pressure monitoring study of XXX HCl (CS-622) in patients with mild-to-moderate essential hypertension.
  52. Open Label Extension of the Dose-Range and Short-Term Efficacy Study of UP XXX in Hypertensive Patients.
  53. Randomized, Double-Blind, Multicenter Trial of 200 mg bid, 100 mg QD, 200 mg QD, and 400 mg QD XXX vs. Placebo in Essential Hypertension.
  54. A Randomized, Multicenter, Double-Blind Study Comparing XXX to Nifedipine GITS (Procardia XL) in the Treatment ofHypertension.
  55. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of XXX Using Ambulatory Blood Pressure Monitoring in Hypertensive Patients.
  56. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Factorial Study to Investigate the Safety and Efficacy of Various Doses of XXX Administered Concomitantly with Various Doses of Losartan in Patients with Mild-to-Moderate Hypertension.
  57. A Double-Blind, Placebo-Controlled, Safety and Efficacy Study of the Effects of 0.75 mg XXX Once Daily Dose in Elderly Patients with Mild or Moderate Essential Hypertension.
  58. Double-Blind, Multicenter, Placebo-Controlled, Parallel Comparison of the Effects of XXX vs Lisinopril alone and in Combination with Hydrochlorothiazide, on Blood Pressure Control, Renal Function, and side Effect Profile in Black Patients with Stage I and II Primary Hypertension.
  59. A Randomized, Double-Blind, Placebo-Controlled Comparison of the Impact of Missed Doses of XXX and Losartan in Patients with Essential Hypertension.
  60. A Single-Blind Sequential Design Study to Determine the Onset of Early Antihypertensive Effect of XXX in Subjects Suffering from Severe HTN and the Response to Increasing the Dose.
  61. A 14-Week, Multicenter, Double-Blind, Parallel Positive-Controlled, Dose Titration Study of XXXÔ Compared to Enalapril in African-American Patients with Mild-to-Moderate Systolic Hypertension.
  62. A 12-Week, Multicenter, Double-Blind, Parallel, Positive-Controlled, Dose Titration Study of XXXÔ (xxx; SK;F 108566-J) Compared to Enalapril in Patients with Severe Systolic Hypertension.
  63. A Multicenter, Open-Label 12-week Prospective Study to Evaluate the Effectiveness and Tolerability of XXX in Hypertensive Patients Participating in the General Registry Program Who Have not Adequately Responded to Angiotensin-Converting Enzyme Inhibitor Monotherapy.
  64. A Multicenter, Double-Blind, 12-Week Randomized Parallel Group, Comparative Study to Evaluate Who Have not Adequately Responded to XXX 10 mg Monotherapy.
  65. An Open-Label, Multicenter Study of XXX (XXX, SK&F 108566J) at Doses of 600, 800, 1200 mg Once Daily in Patients with Severe Systolic Hypertension.
  66. A multicenter, Open-Label Trial to Assess the Effects of XXX on Lipids and Glomerular Permeability in Mild to Moderate Hypertensive Patients.
  67. Placebo Controlled Study of SR XXXin Stage 1 and Stage 2 Hypertension.
  68. Comparative Pharmacokinetics and Pharmacodynamics of XXX in Hypertensive Patients with and without Type II Diabetes Mellitus.
  69. Comparative Effects on Renal Potassium Excretion of XXX Versus XXX in Hypertensive Patients with Type II Diabetes Mellitus.
  70. A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of Ranging Doses of XXX Relative to Placebo, Hydrochlorothiazide and Daily Dose Combinations of XXX and Hydrochlorothiazide for the Treatment of Mild to Moderate Hypertension.
  71. A Long-Term, Open Label Study of the Safety and Efficacy of XXX.
  72. Clinical Protocol for a Double-Blind, Randomized Active-Controlled Comparison Study of the Antihypertensive Effect of XXX Versus Amlodipine in Patients with Elevated Systolic Blood Pressure.
  73. Clinical Protocol for a Double-Blind, Randomized, Active Controlled Comparison Study of the Antihypertensive Renal and Metabolic Effects of XXX Versus Enalapril in Patients with Type II Diabetes Mellitus, Albuminuria and Hypertension.
  74. Anti-thrombotic and Anti-adhesive Endothelial Function in Elderly Minority Patients with Severe Hypertension.
  75. Chart Survey of Patients with Uncontrolled Severe Hypertension
  76. A Randomized, Multicenter, Double-Blind, Parallel Group Study to Determine the Safety and Efficacy of XXX Versus Enalapril in the Treatment of Hypertension in Type 2 Diabetics.
  77. Antihypertensive efficacy of adding XXX XXX to XXX in comparison to up-titration of XXX.
  78. A randomized, placebo-controlled, multicenter, fixed dose study to compare the blood pressure response of patients with moderate hypertension receiving XXX 10 mg, 20 mg, 40 mg, or placebo.
  79. Systolic and pulse pressure hemodynamic improvement by restoring elasticity: The XXX study.
  80. A muticenter, double-blind, randomized, placebo-controlled study to evaluate the effects of a continuous-combined HRT preparation containing 1 mg XXX and 3 mg XXX on blood pressure in mildly hypertensive postmenopausal women.
  81. A multicenter double-blind, randomized, placebo controlled study to evaluate the safety of hormone replacement therapy combination drug product XXXX/XXX in postmenopausal women with concomitant disease and medication known to potentiate the risk of Hyperkalemia.
  82. A multi-national prospective, randomized, double-blind, multi-center, placebo-controlled, study to evaluate efficacy and safety of a fixed combination therapy of XXX and XXX in the treatment of concurrent hypertension and hyperlipidemia.
  83. A double-blind comparison of the effects of XXX and XXX on the occurrence of peripheral edema in hypertensive patients.
  84. A randomized, double-blind, multicenter, multifactorial, placebo-controlled, parallel group study to evaluate the efficacy and safety of XXX and XXX combined and alone in hypertensive patients.